Logistics boost: A technician checking the production line of the first batch of Sinovac Biotech’s Covid-19 vaccine CoronaVac at Pharmaniaga Life Science’s plant in Puchong. The firm’s upside is its earnings contribution from the Covid-19 vaccine supply and distribution.
PETALING JAYA: Pharmaniaga Bhd
is expected to see a normalisation in demand for financial year 2021 (FY21) after witnessing a decline in revenue for FY20.
The company’s FY20 revenue dipped 3.4% as it saw lower sales from its core concession business for its logistics and distribution (L&D) segment due to disruptions in demand from both the public and private healthcare facilities.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
